FyMed Demonstrates Superiority of FY101C Over Ibuprofen and Naproxen in the Treatment of Pain and Inflammation
FyMed, Inc. today announced results from comparative in-vivo studies of FY101C, its lead NSAID candidate, which demonstrated significant superiority to conventional NSAIDs in terms of efficacy and safety in the management of acute and chronic pain and inflammation. - July 25, 2012
FyMed Reinforces Its Drug Development Pipeline with Novel Strategies in Personalized Medicine
FyMed, Inc., a biopharmaceutical company utilizing proprietary methodologies in evidence-based medicine for drug discoveries, recently announced plans for the strategic and operational reinforcements of their drug development pipeline through innovative approaches in personalized medicine. - October 06, 2011
Press Releases 1 - 2 of 2